Cocrystal Pharma Inc（COCP）股票分析COCPCocrystal Pharma Inc

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cocrystal Pharma Inc is currently not a strong buy due to its ongoing financial struggles and recent stock performance. The stock closed at $1.10, down 4.35% over the last five days, and has a negative forward P/E ratio of 0, indicating no expected earnings growth in the near term. While the recent FDA Fast Track designation for CDI-988 is a positive catalyst, the company reported a significant net loss of $3.16 million in Q2 2026, raising concerns about its financial stability. The RSI is at 45.67, suggesting the stock is neither overbought nor oversold, which supports a hold position rather than a buy. The main risk is the company's liquidity pressure, with unrestricted cash decreasing from $7.7 million to $4.7 million in just a few months, which could impact operations.

1 analysts cover COCP: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.